{"article":{"annotation":{"article_id":"paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026","available_at":"2026-11-20T15:14:49.019516Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"3e9498f512464ec0e06f38ba029e87adcc55e1c4da6a995aa6a916fd5e57104c","input_sha256":"f4ecb38707a43ccec1d7d617c2afa762caaf8ec5b61a48d1154a716fa2d7b8e1","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"US","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.prnewswire.com/news-releases/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026-302939854.html"]}],"geometry":null,"id":"iso3166-1:US","kind":"country-or-area","labels":{"ar":"الولايات المتحدة الأمريكية","en":"United States of America","es":"Estados Unidos de América","fr":"États-Unis d’Amérique"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:20000447","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: cancer","source_urls":["https://www.prnewswire.com/news-releases/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026-302939854.html"]}],"method":"controlled-rules-v1","rule_id":"cancer","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["PAQ Therapeutics, a clinical-stage biotechnology company based in Burlington, Massachusetts, announced on 20 November 2026 the first clinical data from its ongoing Phase 1 trial of PT0253, an investigational intravenous small-molecule degrader targeting the KRAS G12D mutant protein. The preliminary results from study NCT06797336 were presented in a late-breaking oral session by Alexander I. Spira of NEXT Oncology Virginia at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company stated that the findings reflect an October 23, 2026 clinical data cutoff.","In the monotherapy dose-escalation portion of the trial, 44 patients with KRAS G12D-mutant advanced solid tumors received weekly intravenous infusions of PT0253 at doses ranging from 10 to 750 mg. Enrolled patients had received a median of 2.5 prior lines of therapy, and 27 percent had previously been treated with a KRAS- or RAS-targeted agent. The trial is designed to evaluate safety and tolerability and to identify the maximally tolerated dose or recommended Phase 2 dose in adult patients with advanced KRAS G12D-mutant solid tumors.","Across the full evaluated monotherapy dose range of 10 to 750 mg, investigators observed no dose-limiting toxicities. Among the 27 patients treated at higher dose levels from 120 to 750 mg, treatment-related adverse events were predominantly Grade 1 or Grade 2 in severity. Only one patient, representing 4 percent of that cohort, experienced a Grade 3 or higher treatment-related adverse event. PAQ Therapeutics reported no serious treatment-related adverse events, no treatment discontinuations caused by treatment-related adverse events, and no requirement for PT0253-specific pre-treatment prophylaxis.","Monotherapy antitumor activity appeared across dose levels of 120 mg and higher in patients with colorectal, pancreatic and lung cancers. In refractory colorectal cancer, three of six patients treated at 120 mg or above achieved unconfirmed partial responses, including one patient whose tumor had previously progressed on a KRAS-targeted therapy. PAQ Therapeutics noted that these early observations are consistent with the scientific hypothesis that catalytic degradation of KRAS G12D may counter EGFR-mediated feedback reactivation seen with conventional KRAS inhibitors, though confirmation in larger cohorts remains necessary.","In the pancreatic cancer monotherapy subgroup treated at 120 mg and above, three of ten patients who had not previously received KRAS- or RAS-targeted therapy achieved confirmed partial responses, with most responses deepening over time, and nine of ten patients achieved disease control. Separately, among 12 patients across the study whose disease had progressed on prior KRAS- or RAS-targeted therapies, six patients, or 50 percent, achieved disease control. Because these subgroups remain small and early-stage, the company cautioned that preliminary Phase 1 figures are subject to ongoing monitoring and may shift as follow-up matures.","PAQ Therapeutics also presented initial combination data in first-line metastatic pancreatic cancer, where 14 patients received weekly PT0253 at 350 mg alongside modified FOLFIRINOX, a standard-of-care multi-agent chemotherapy regimen. As of the October 23, 2026 cutoff, 13 of those 14 patients remained on treatment. Among the seven patients who had completed at least two post-baseline tumor scans, six achieved objective responses, comprising one confirmed complete response and five partial responses, four of which were confirmed.","The combination regimen was reported to be generally well tolerated, with a safety profile consistent with modified FOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific pre-treatment prophylaxis. Median relative dose intensity reached 91 percent for PT0253, while modified FOLFIRINOX dose intensity ranged from 75 to 80 percent across its chemotherapy components, matching the expected clinical range for the regimen. Maintaining standard chemotherapy dose intensity is a key practical test for investigational first-line pancreatic cancer add-on agents.","Chief executive officer Nan Ji said the early safety profile, single-agent antitumor signals and initial combination activity support advancing PT0253 into pancreatic and colorectal cancer expansion cohorts. Chief medical officer Andrew P. Krivoshik highlighted the absence of dose-limiting toxicities and the preservation of expected chemotherapy dose intensity as evidence of combinability. Presenter Alexander I. Spira noted that patients with KRAS G12D-mutant tumors who progress after chemotherapy and KRAS-targeted drugs have limited options, adding that expansion cohorts will be essential to evaluate these preliminary signals.","Beyond PT0253, PAQ Therapeutics is conducting Phase 1 clinical testing of PT0511, an investigational pan-KRAS protein degrader for advanced solid tumors. Neither compound has regulatory approval, and the ENA 2026 disclosure represents an early-stage, non-randomized dataset from a small number of evaluable patients. Confirmation of unconfirmed responses, durability of tumor shrinkage, progression-free survival and safety over longer treatment exposure in upcoming expansion cohorts will be needed before pivotal clinical development can be assessed."],"sections":[]},"corrections":[],"country":"US","data":{"blocks":[{"description":{"ar":"أرقام سريرية أولية مختارة للعلاج الأحادي والمركب بدواء PT0253 في المرحلة الأولى حتى تاريخ قطع البيانات في 23 أكتوبر 2026.","de":"Ausgewählte vorläufige klinische Phase-1-Zahlen zu PT0253 in Monotherapie und Kombination zum Datenstichtag 23. Oktober 2026.","en":"Selected preliminary Phase 1 monotherapy and combination clinical figures for PT0253 as of the October 23, 2026 data cutoff.","es":"Cifras clínicas preliminares seleccionadas de fase 1 para PT0253 en monoterapia y combinación al 23 de octubre de 2026.","fr":"Chiffres cliniques préliminaires sélectionnés de phase 1 pour PT0253 en monothérapie et en association au 23 octobre 2026.","pt":"Valores clínicos preliminares selecionados de fase 1 para o PT0253 em monoterapia e combinação em 23 de outubro de 2026.","tr":"23 Ekim 2026 veri kesim tarihi itibarıyla PT0253 için seçilmiş ön Faz 1 monoterapi ve kombinasyon klinik rakamları."},"id":"reported-figures","items":[{"basis":"observed","label":{"ar":"عدد المرضى المعالجين في تصعيد جرعة العلاج الأحادي بدواء PT0253","de":"Behandelte Patienten in der PT0253-Monotherapie-Dosiseskalation","en":"Patients treated in PT0253 monotherapy dose escalation","es":"Pacientes tratados en el escalado de dosis en monoterapia de PT0253","fr":"Patients traités dans l'escalade de dose en monothérapie PT0253","pt":"Doentes tratados no escalonamento de dose em monoterapia com PT0253","tr":"PT0253 monoterapi doz artırma grubunda tedavi edilen hasta sayısı"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"united-states","id":"g20261120-d7-paq-1","periodRole":"reference-period","unitCode":"count"},"period":"2026-10-23","unit":"patients","value":44},{"basis":"observed","label":{"ar":"نسبة الآثار الجانبية المرتبطة بالعلاج من الدرجة 3 فأعلى عند 120-750 ملغ","de":"Anteil behandlungsbedingter Nebenwirkungen ab Grad 3 bei 120-750 mg","en":"Rate of Grade 3 or higher treatment-related adverse events at 120-750 mg","es":"Tasa de efectos adversos relacionados con el tratamiento de grado 3 o superior a 120-750 mg","fr":"Taux d'effets indésirables liés au traitement de grade 3 ou plus à 120-750 mg","pt":"Taxa de acontecimentos adversos relacionados de grau 3 ou superior entre 120 e 750 mg","tr":"120-750 mg dozlarında 3. derece ve üzeri tedaviyle ilişkili yan etki oranı"},"measure":{"aggregation":"rate","frequency":"irregular","geography":"united-states","id":"g20261120-d7-paq-2","periodRole":"reference-period","unitCode":"percent"},"period":"2026-10-23","unit":"percent","value":4},{"basis":"observed","label":{"ar":"معدل السيطرة على المرض لدى المرضى بعد علاج سابق موجه ضد KRAS/RAS","de":"Krankheitskontrollrate nach vorheriger KRAS/RAS-gerichteter Therapie","en":"Disease control rate in patients after prior KRAS/RAS-targeted therapy","es":"Tasa de control de la enfermedad tras terapia previa dirigida a KRAS/RAS","fr":"Taux de contrôle de la maladie après un traitement antérieur ciblant KRAS/RAS","pt":"Taxa de controlo da doença após terapêutica prévia dirigida a KRAS/RAS","tr":"Önceki KRAS/RAS hedefli tedavi sonrası hastalarda hastalık kontrol oranı"},"measure":{"aggregation":"rate","frequency":"irregular","geography":"united-states","id":"g20261120-d7-paq-3","periodRole":"reference-period","unitCode":"percent"},"period":"2026-10-23","unit":"percent","value":50},{"basis":"observed","label":{"ar":"مرضى سرطان البنكرياس في الخط الأول المعالجون بـ PT0253 مع mFOLFIRINOX","de":"Erstlinien-Pankreaskrebspatienten unter PT0253 plus mFOLFIRINOX","en":"First-line pancreatic cancer patients treated with PT0253 plus mFOLFIRINOX","es":"Pacientes con cáncer de páncreas en primera línea tratados con PT0253 más mFOLFIRINOX","fr":"Patients atteints de cancer du pancréas en première ligne traités par PT0253 et mFOLFIRINOX","pt":"Doentes com cancro do pâncreas em primeira linha tratados com PT0253 mais mFOLFIRINOX","tr":"PT0253 ve mFOLFIRINOX alan birinci basamak pankreas kanseri hastaları"},"measure":{"aggregation":"stock","frequency":"irregular","geography":"united-states","id":"g20261120-d7-paq-4","periodRole":"reference-period","unitCode":"count"},"period":"2026-10-23","unit":"patients","value":14},{"basis":"observed","label":{"ar":"وسيط كثافة الجرعة النسبية لدواء PT0253 في مجموعة العلاج المركب","de":"Mediane relative Dosisintensität von PT0253 in der Kombinationskohorte","en":"Median relative dose intensity of PT0253 in combination cohort","es":"Mediana de intensidad de dosis relativa de PT0253 en la cohorte combinada","fr":"Intensité de dose relative médiane de PT0253 dans la cohorte combinée","pt":"Mediana da intensidade de dose relativa do PT0253 na coorte combinada","tr":"Kombinasyon grubunda PT0253 ortanca göreli doz yoğunluğu"},"measure":{"aggregation":"rate","frequency":"irregular","geography":"united-states","id":"g20261120-d7-paq-5","periodRole":"reference-period","unitCode":"percent"},"period":"2026-10-23","unit":"percent","value":91}],"methodology":{"ar":"تحتفظ الأرقام بالمجموعات وتاريخ قطع البيانات والتعريفات التي يحددها المصدر، والنتائج المبكرة للمرحلة الأولى أولية وتخضع للمتابعة المستمرة.","de":"Die Zahlen behalten Kohorten, Datenstichtag und Definitionen der Quelle bei. Frühe Phase-1-Daten sind vorläufig und unterliegen laufender Prüfung.","en":"Figures retain the source's stated cohorts, data cutoff and definitions. Early Phase 1 results are preliminary and subject to ongoing monitoring. No missing value is inferred.","es":"Las cifras conservan las cohortes, la fecha de corte y las definiciones de la fuente. Los resultados de fase 1 son preliminares y están sujetos a seguimiento.","fr":"Les chiffres conservent les cohortes, la date de clôture et les définitions de la source. Les résultats de phase 1 sont préliminaires et soumis au suivi en cours.","pt":"Os valores mantêm as coortes, a data de corte e as definições da fonte. Os resultados iniciais de fase 1 são preliminares e sujeitos a monitorização contínua.","tr":"Rakamlar kaynağın belirttiği grupları, veri kesim tarihini ve tanımları korur. Erken Faz 1 sonuçları ön niteliktedir ve izlem sürmektedir. Eksik değerler çıkarımla tamamlanmaz."},"sourceUrls":["https://www.prnewswire.com/news-releases/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026-302939854.html"],"title":{"ar":"الأرقام الرئيسية المعلنة","de":"Wichtige gemeldete Kennzahlen","en":"Key reported figures","es":"Cifras clave comunicadas","fr":"Principaux chiffres déclarés","pt":"Principais valores reportados","tr":"Bildirilen temel rakamlar"},"type":"metrics","updatedAt":"2026-11-20T14:30:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026/data/reported-figures?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026/data/reported-figures?lang=en&format=json"},"id":"reported-figures"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-eb82db14-378e-55e3-a92e-86a02f0de7ff","event_period":"2026-11-20","event_period_basis":"event-or-reference-period","id":"paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-20T15:14:29+00:00","publication_basis":"publication-record","published_at":"2026-11-20T15:14:29+00:00","reading_minutes":4,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026","sources":[{"checkedAt":"2026-11-20","name":"PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 2026","publishedAt":"2026-11-20","url":"https://www.prnewswire.com/news-releases/paq-therapeutics-presents-first-clinical-data-for-pt0253-a-selective-kras-g12d-degrader-showing-a-differentiated-safety-profile-and-antitumor-activity-at-ena-2026-302939854.html"}],"summary":"PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.","text":"PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.\n\nPAQ Therapeutics, a clinical-stage biotechnology company based in Burlington, Massachusetts, announced on 20 November 2026 the first clinical data from its ongoing Phase 1 trial of PT0253, an investigational intravenous small-molecule degrader targeting the KRAS G12D mutant protein. The preliminary results from study NCT06797336 were presented in a late-breaking oral session by Alexander I. Spira of NEXT Oncology Virginia at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company stated that the findings reflect an October 23, 2026 clinical data cutoff.\n\nIn the monotherapy dose-escalation portion of the trial, 44 patients with KRAS G12D-mutant advanced solid tumors received weekly intravenous infusions of PT0253 at doses ranging from 10 to 750 mg. Enrolled patients had received a median of 2.5 prior lines of therapy, and 27 percent had previously been treated with a KRAS- or RAS-targeted agent. The trial is designed to evaluate safety and tolerability and to identify the maximally tolerated dose or recommended Phase 2 dose in adult patients with advanced KRAS G12D-mutant solid tumors.\n\nAcross the full evaluated monotherapy dose range of 10 to 750 mg, investigators observed no dose-limiting toxicities. Among the 27 patients treated at higher dose levels from 120 to 750 mg, treatment-related adverse events were predominantly Grade 1 or Grade 2 in severity. Only one patient, representing 4 percent of that cohort, experienced a Grade 3 or higher treatment-related adverse event. PAQ Therapeutics reported no serious treatment-related adverse events, no treatment discontinuations caused by treatment-related adverse events, and no requirement for PT0253-specific pre-treatment prophylaxis.\n\nMonotherapy antitumor activity appeared across dose levels of 120 mg and higher in patients with colorectal, pancreatic and lung cancers. In refractory colorectal cancer, three of six patients treated at 120 mg or above achieved unconfirmed partial responses, including one patient whose tumor had previously progressed on a KRAS-targeted therapy. PAQ Therapeutics noted that these early observations are consistent with the scientific hypothesis that catalytic degradation of KRAS G12D may counter EGFR-mediated feedback reactivation seen with conventional KRAS inhibitors, though confirmation in larger cohorts remains necessary.\n\nIn the pancreatic cancer monotherapy subgroup treated at 120 mg and above, three of ten patients who had not previously received KRAS- or RAS-targeted therapy achieved confirmed partial responses, with most responses deepening over time, and nine of ten patients achieved disease control. Separately, among 12 patients across the study whose disease had progressed on prior KRAS- or RAS-targeted therapies, six patients, or 50 percent, achieved disease control. Because these subgroups remain small and early-stage, the company cautioned that preliminary Phase 1 figures are subject to ongoing monitoring and may shift as follow-up matures.\n\nPAQ Therapeutics also presented initial combination data in first-line metastatic pancreatic cancer, where 14 patients received weekly PT0253 at 350 mg alongside modified FOLFIRINOX, a standard-of-care multi-agent chemotherapy regimen. As of the October 23, 2026 cutoff, 13 of those 14 patients remained on treatment. Among the seven patients who had completed at least two post-baseline tumor scans, six achieved objective responses, comprising one confirmed complete response and five partial responses, four of which were confirmed.\n\nThe combination regimen was reported to be generally well tolerated, with a safety profile consistent with modified FOLFIRINOX alone and low gastrointestinal toxicity without PT0253-specific pre-treatment prophylaxis. Median relative dose intensity reached 91 percent for PT0253, while modified FOLFIRINOX dose intensity ranged from 75 to 80 percent across its chemotherapy components, matching the expected clinical range for the regimen. Maintaining standard chemotherapy dose intensity is a key practical test for investigational first-line pancreatic cancer add-on agents.\n\nChief executive officer Nan Ji said the early safety profile, single-agent antitumor signals and initial combination activity support advancing PT0253 into pancreatic and colorectal cancer expansion cohorts. Chief medical officer Andrew P. Krivoshik highlighted the absence of dose-limiting toxicities and the preservation of expected chemotherapy dose intensity as evidence of combinability. Presenter Alexander I. Spira noted that patients with KRAS G12D-mutant tumors who progress after chemotherapy and KRAS-targeted drugs have limited options, adding that expansion cohorts will be essential to evaluate these preliminary signals.\n\nBeyond PT0253, PAQ Therapeutics is conducting Phase 1 clinical testing of PT0511, an investigational pan-KRAS protein degrader for advanced solid tumors. Neither compound has regulatory approval, and the ENA 2026 disclosure represents an early-stage, non-randomized dataset from a small number of evaluable patients. Confirmation of unconfirmed responses, durability of tumor shrinkage, progression-free survival and safety over longer treatment exposure in upcoming expansion cohorts will be needed before pivotal clinical development can be assessed.","title":"PAQ Therapeutics presents first Phase 1 clinical data for KRAS G12D degrader PT0253 at ENA 2026","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},{"api_url":"https://newsverum.com/api/v1/articles/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"}],"url":"https://newsverum.com/en/news/paq-therapeutics-pt0253-kras-g12d-degrader-phase-1-data-ena-2026"},"version":"1"}
